Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9289346 | Virus Research | 2005 | 8 Pages |
Abstract
The prevalence of HIV-1 drug resistance mutations in naïve patients has been previously shown to differ greatly with the geographic origin. The purpose of this study was to prospectively estimate the prevalence of HIV-1 drug resistance in Greece by analyzing a representative sample of newly HIV-1 diagnosed patients, as part of the SPREAD collaborative study. Protease (PR) and partial reverse transcriptase (RT) sequences were determined from 101 newly diagnosed HIV-1 patients, in Greece, during the period September 2002-August 2003, representing one-third of the total newly diagnosed HIV-1 patients in the same time period. The prevalence of HIV-1 drug resistance was estimated according to the IAS-USA mutation table taking into account all mutations in RT and only major mutations in PR region. The overall prevalence of resistance was 9% [95% confidence interval (CI): 4.2-16.2%]. The prevalence of mutations associated with resistance to NRTIs was 5% (95% CI: 1.6-11.2%), for NNRTIs was 4% (95% CI: 1.1-9.8%), while no major resistance mutations were found in PR. No multi-class resistance was detected in the study population. The prevalence of resistant mutations in the recent seroconverters was 22%. For two individuals, there was clear evidence for transmitted resistance based on epidemiological information for a known source of HIV-1 transmission. The prevalence of the HIV-1 non-B subtypes and recombinants was 52%.
Related Topics
Life Sciences
Immunology and Microbiology
Virology
Authors
D. Paraskevis, E. Magiorkinis, A. Katsoulidou, E. Hatzitheodorou, A. Antoniadou, A. Papadopoulos, G. Poulakou, V. Paparizos, C. Botsi, N. Stavrianeas, M. Lelekis, M. Chini, P. Gargalianos, N. Magafas, M. Lazanas, G. Chryssos, G. Petrikkos, G. Panos,